S&P Vs. Pharma Partnership Deal Volume
Executive Summary
Pharma partnership deal volume was very positively correlated with the S&P Index for much of the past decade, but then followed an inverse correlation from around the time of the recession to the present day.
You may also be interested in...
Big Pharma Licensing Growth Slows In 2016
Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.